Revvity has acquired companies in sectors with high-growth potential, such as cell and gene therapies, and precision medicine, among other sectors. The company has strengthened its debt position ...

Jan 31 (Reuters) - Medical equipment maker Revvity (RVTY.N), opens new tab forecast full-year profit and revenue for 2025 below Wall Street estimates on Friday, as it expects soft demand for its ...

Life sciences company Revvity (NYSE:RVTY) in Q4 CY2024, with sales up 4.8% year on year to $729.4 million. On the other hand, the company’s full-year revenue guidance of $2.83 billion at the ...

WALTHAM, Mass., January 31, 2025--Revvity, Inc. (NYSE: RVTY) today reported financial results for the fourth quarter and full year ended December 29, 2024. WALTHAM ...

WALTHAM, Mass.--(BUSINESS WIRE)-- Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor ...

After significant business transformation activities in recent years, Revvity (formerly PerkinElmer) has been in a constant state of evolution since 2016 when the company made the transition into ...

Replays of the presentations will be posted on the Revvity Investor Relations website after the events and will be available for at least 30 days. At Revvity, “impossible” is inspiration ...

Life sciences company Revvity (NYSE:RVTY) met Wall Street’s revenue expectations in Q4 CY2024, with sales up 4.8% year on year to $729.4 million. On the other hand, the company’s full-year ...

KeyBanc analyst Paul Knight maintained a Buy rating on Revvity (RVTY – Research Report) today and set a price target of $145.00. The company’s shares closed last Friday at $126.13. Leverage ...

WALTHAM, Mass. (AP) — WALTHAM, Mass. (AP) — Revvity, Inc. (RVTY) on Friday reported fourth-quarter net income of $94.6 million. The Waltham, Massachusetts-based company said it had net income ...

CEO Prahlad Singh highlighted that Revvity achieved 6% organic growth in Q4 2024, with adjusted operating margins exceeding 30% and adjusted EPS reaching $1.42, surpassing expectations.